BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11168950)

  • 1. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.
    D'Amico G; Napodano P; Ferrario F; Rastaldi MP; Arrigo G
    Kidney Int; 2001 Feb; 59(2):682-92. PubMed ID: 11168950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological features in IgA nephropathy.
    Ferrario F; Rastaldi MP; Napodano P
    Ann Med Interne (Paris); 1999 Feb; 150(2):108-16. PubMed ID: 10392259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid and cyclophosphamide in IgA nephropathy.
    Roccatello D; Ferro M; Cesano G; Rossi D; Berutti S; Salomone M; Piccoli G; Sena LM
    Nephrol Dial Transplant; 2000 Jun; 15(6):833-5. PubMed ID: 10831636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
    Haas M; Jafri J; Bartosh SM; Karp SL; Adler SG; Meehan SM
    Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
    J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy.
    Kusano T; Takano H; Kang D; Nagahama K; Aoki M; Morita M; Kaneko T; Tsuruoka S; Shimizu A
    Hum Pathol; 2016 Mar; 49():135-44. PubMed ID: 26826420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
    Tumlin JA; Hennigar RA
    Semin Nephrol; 2004 May; 24(3):256-68. PubMed ID: 15156530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S; Söderberg MP; Berg UB
    Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.
    Roccatello D; Ferro M; Coppo R; Giraudo G; Quattrocchio G; Piccoli G
    Nephrol Dial Transplant; 1995 Nov; 10(11):2054-9. PubMed ID: 8643167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasculitic IgA nephropathy: prognosis and outcome.
    Pankhurst T; Lepenies J; Nightingale P; Howie AJ; Adu D; Harper L
    Nephron Clin Pract; 2009; 112(1):c16-24. PubMed ID: 19342865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of IgA nephropathy with chronic renal failure].
    Pozzi C
    G Ital Nefrol; 2008; 25 Suppl 44():83-7. PubMed ID: 19048591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
    Rasche FM; Klotz CH; Czock D; Karges W; Muche R; Jehle PM; Mertz A; Keller F
    Nephron Clin Pract; 2003; 93(4):c131-6. PubMed ID: 12759581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
    Fernandes PF; Júnior GB; Barros FA; Sousa DC; Franco LM; Patrocínio RM
    Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting progression of IgA nephropathies.
    Coppo R; D'Amico G
    J Nephrol; 2005; 18(5):503-12. PubMed ID: 16299675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
    Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T; Najafi I; Salimi BH; Broomand B
    Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of progressive IgA nephropathy: an update.
    Wang W; Chen N
    Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.